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Vitamin E prevents renal dysfunction induced by experimental
chronic bile duct ligation.
Background. The mechanisms by which prolonged cholesta-
sis alters renal hemodynamics and excretory function are un-
known but may be related to increased oxidative stress, with
subsequent formation of lipid peroxidation–derived products
(e.g., F2-isoprostanes) and endothelin (ET). We investigated
whether antioxidant therapy prevents chronic bile duct ligation
(CBDL)–induced alterations in systemic and renal hemody-
namics, and reduces F2-isoprostane and ET levels.
Methods. Sprague-Dawley rats were placed on either a nor-
mal or a high vitamin E diet for 7 days and then underwent
either CBDL or sham surgery. They were then maintained
on their respective diets for 21 more days, at which time the
physiologic studies were performed.
Results. Thirty-three percent of the CBDL rats died by day
21. The remaining rats had a lower mean arterial pressure (MAP),
renal blood flow (RBF), glomerular filtration rate (GFR), and
sodium and water excretion than control rats. CBDL rats had
higher portal pressure, renal venous pressure, and renal vascu-
lar resistance (RVR). These changes were associated with in-
creased levels of systemic and renal venous F2-isoprostanes
and ET. Vitamin E normalized MAP, RBF, GFR, RVR, and
sodium and water excretion, and improved the 21-day survival
without altering portal or renal venous pressures. Surprisingly,
vitamin E did not alter the systemic levels of F2-isoprostanes but
markedly reduced their levels in the renal venous circulation.
Conclusion. Vitamin E improves MAP and renal function
in CBDL rats, and selectively decreases renal levels of oxidative
stress and ET, suggesting that local redox balance is implicated
in CBDL-induced renal dysfunction.
Advancing liver disease leads to marked alterations
in the systemic circulation and in renal function. The
systemic circulation is characterized by a hyperdynamic
state. That is, there is increased cardiac output, plasma
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volume, and splanchnic blood flow, and decreased pe-
ripheral resistance that leads to a decreased mean arterial
pressure (MAP) [1]. Yet, despite the hyperdynamic cir-
culation and prominent peripheral vasodilation, the re-
nal vasculature is markedly vasoconstricted and renal
sodium and water handling is impaired [2–10]. Because
these alterations can precipitate many of the complica-
tions of liver disease, much effort has been aimed at eluci-
dating the potential mechanisms that lead to the renal
dysfunction. For instance, activation of vasoconstrictor sys-
tems such as the renin-angiotensin-aldosterone system,
the sympathetic nervous system, vasopressin, and endo-
thelin (ET) [3, 11] have been extensively evaluated, yet
none has been convincingly demonstrated to be selec-
tively responsible for the renal dysfunction. Recently, a
new potential culprit has received increasing attention—
oxidative stress [12–16]. This interest stems from the
finding that oxidative stress is markedly elevated during
liver disease and can have profound effects on hemody-
namics and renal function. Interestingly, it induces renal
vasoconstriction not only by quenching nitric oxide (NO),
but also by increasing production of F2-isoprostanes
[17–19] and ET [20, 21]. Both of these factors are mark-
edly increased in the plasma and urine from patients and
rats with liver disease [22–26], and especially in patients
with hepatorenal syndrome [24, 26], raising the possibil-
ity that they may play a role in this condition. Indeed,
antioxidants may delay the development of a hyperdy-
namic circulatory state in experimental cirrhosis [23, 27].
However, it is unknown whether antioxidants can also
protect renal function during liver disease. Thus, in the
present study, we hypothesized that liver disease in-
creases oxidative stress, which in turn contributes to the
alterations in blood pressure and renal function. To test
this hypothesis, we examined whether administering sup-
plemental vitamin E prevents the fall in blood pressure,
the profound renal vasoconstriction, and the impaired
renal excretory function in rats with chronic bile duct
ligation (CBDL), a model of cholestatic liver disease. In
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addition, we speculated that the changes in oxidant stress
may be more pronounced intrarenally than systemically
(due to direct effects of bile acids on renal tubular cells,
and the higher renal levels of pro-oxidant hormones such
as angiotensin II). Thus, we also measured oxidant stress
markers (F2-isoprostanes) in the renal venous circula-
tion. Finally, because F2-isoprostanes can increase ET
production (with the potential to cause further deteriora-
tion of renal function), we tested whether any changes in
renal function during the antioxidant therapy are accom-
panied by changes in either systemic or renal ET levels.
METHODS
All experiments were in compliance with the Guide
for the Care and Use of Laboratory Animals, formulated
by the U.S. National Institutes of Health, and this proto-
col was approved by the Institutional Animal Care and
Use Committee of the Mayo Foundation.
Experimental protocols
Adult male Sprague-Dawley rats (325–350 g; Charles
River Laboratories, Omaha, NE, USA) were random-
ized into 4 groups: (1) untreated controls (N  8); (2)
vitamin E–treated controls (N 5); (3) untreated CBDL
rats (N 18); and (4) vitamin E–treated CBDL rats (N
9). The rats were then placed in metabolic cages and
received food and water ad libitum. Groups 1 and 3
(normal vitamin E groups) received standard rat chow
with normal vitamin E content (50 IU/kg diet), whereas
groups 2 and 4 (high vitamin E groups) were given rat
chow containing 5000 IU/kg diet of dry vitamin E acetate.
After 1 week, the rats were subjected to either a sham
surgery (control: groups 1 and 2), or CBDL surgery
(groups 3 and 4), as previously described [28]. Briefly,
rats were anesthetized with an intramuscular injection
of xylazine (50 mg/kg b/w; Lloyd Laboratories, Shenan-
doah, IA, USA) and ketamine (100 mg/kg b/w; Fort
Dodge Laboratories, Inc., Fort Dodge, IA, USA) and a
midline incision was made under the sternum. The bile
duct was then exposed, doubly ligated with a 2-0 silk
suture, and excised between the ligatures (CBDL groups),
or only exposed and dissected, but not ligated or cut
(sham groups). After closure of the abdominal wound,
each animal received a subcutaneous injection of Dura-
pen 0.01 mL/100gm b/w (Penicillin-G-Benzatine and
Penicillin-G-procaine; VEDCO, St. Joseph, MO, USA).
After recovering from surgery, the rats were returned
to metabolic cages. Measurements of water and food
intake, body weight, and urinary sodium and volume
were undertaken at days 7, 14, and 20 after surgery.
Urine samples were centrifuged to remove solid matter
before analysis. Twenty-one days after the surgery we
performed renal function studies on the surviving rats,
after which blood and tissue samples were collected for
biochemical and histologic analysis.
Procedures for determining mean arterial pressure
and renal function in anesthetized rats, and for
harvesting blood and tissue
Rats were anesthetized with thiobutabarbital 100
mg/kg b/w intraperitoneal (Inactin, BYK-Gudden, Con-
stance, Germany), placed on a heated table to maintain
body temperature at 37C, and a tracheotomy was per-
formed to facilitate respiration (PE-240). We cannulated
(PE-50) the right femoral vein for infusions, and the
artery for collecting blood samples and measuring MAP
(recorded continuously via a Gould 8188G-402 pressure
transducer and register 8188-4400, Gould, Inc., Cleve-
land, OH, USA). Renal blood flow (RBF) and glomeru-
lar filtration rate (GFR) were determined via standard
p-aminohippuric acid (PAH) and inulin clearance tech-
niques [10], respectively. For this, the rats were continu-
ously infused with 0.9% saline containing 1.5% albumin,
1% inulin, and 1% PAH (all from Sigma Chemical Co.,
St. Louis, MO, USA) at a rate of 1.5 mL/h/100 g/bw. The
urinary bladder was cannulated (PE-90) via a suprapubic
incision to obtain urine samples into pre-weighed plastic
tubes. A 60-minute stabilization period was allowed,
after which urine was collected for two 15-minute clear-
ance periods. Blood samples were drawn at the midpoint
of each period for hematocrit, inulin, and PAH measure-
ments. Urine flow was determined gravimetrically. Uri-
nary sodium concentration was measured by flame pho-
tometry (IL943TM; Instrumentation Laboratory, Lexington,
MA, USA) and sodium excretion was calculated as the
product of sodium concentration and urine flow. All the
variables from the two control periods were averaged
and factored per gram of kidney tissue.
Upon completing the clearance experiments, we mea-
sured portal and renal venous pressures by direct cannu-
lation of the ileocolic and renal veins with the tip of a
22GA-needle connected to a PE-50 tube. The pressure
was recorded using a 0–20 mm Hg transducer that was
calibrated prior to each recording with the zero reference
point being the midportion of the rat. After completion
of the measurements, we obtained arterial and renal
venous plasma samples and stored them at 80C to
measure plasma renin activity (PRA), isoprostanes, thio-
barbituric acid reactive substances (TBARS), and ET.
After the blood samples were collected, the animals were
killed, and their livers and kidneys removed (the kidneys
were blotted and weighed). These samples were then
immersed and fixed in phosphate-buffered formol for
histologic analysis.
Telemetry study to determine the development of
hypotension in conscious, CBDL rats
Because cholestasis may predispose rats to hypoten-
sion during anesthesia (which may have tainted our blood
pressure measurements) we ran separate experiments
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in which we continuously monitored blood pressure in
conscious, unrestrained control and CBDL rats. For this,
we implanted a continuous telemetry device (Data Sci-
ences, Inc., St. Paul, MN, USA) during the surgical pro-
cedure for CBDL/sham. While the animals were anesthe-
tized, we isolated the femoral artery on the left side of
the animal through a small incision on the inner leg.
Next, a small incision was made in the lower left quadrant
and a subcutaneous pocket was made for placement of
the transmitter body. The pocket and femoral artery
were rinsed with sterile saline. The transmitter was in-
serted into the subcutaneous pocket and the transmitter
catheter was drawn just above the isolated femoral ar-
tery. The artery was cannulated with the transmitter
catheter and the catheter was fixed with a small suture.
The transmitter body was then sutured in place against
the abdomen wall and the skin was closed with wound
closure clips. At the end of the procedure each animal
was given a subcutaneous injection of antibiotics (Dura-
pen; Penicillin-G-Benzatine and Penicillin-G-Procaine,
0.05 mL/100 g/bw) and subcutaneous analgesia (Bupre-
morphine, 0.01–0.05 mg/kg). The animals were given a
two-day recuperation period and then we began collect-
ing continuous blood pressure data every 10 minutes for
the duration of the study. We compared the MAP data
collected via telemetry to that collected during the acute
physiologic studies under anesthesia.
Biochemical determinations
We estimated PRA by radioimmunoassay (RIA) of
angiotensin I generated (Dupon, NEN Research Prod-
ucts, Boston, MA, USA), as described [29]. Free isopros-
tanes in plasma were measured using extraction and
enzyme immunoassay (EIA) procedures following a
modification of the methods provided in the isoprostanes
measurement kit from Cayman Chemical (Ann Arbor,
MI, USA) as described [30]. Plasma TBARS were deter-
mined by a colorimetric method [30], and ET measured
using an ET RIA kit (Peninsula Laboratories, Inc., Bel-
mont, CA, USA) after disposable column extraction
(Sep-Pak C18; Millipore Corp., Milford, MA, USA) [30].
Blood was also collected from another four groups of
rats (treated in an identical manner to the ones above)
for measurement of liver function parameters. The liver
function parameters, alkaline phosphatase (ALKP), ala-
nine transaminase (ALT), aspartate transaminase (AST),
and total bilirubin (BR), were measured by colorimetric
assay using an automated method (Autoanalyzer Hitachi
747, Roche Diagnostics, Indianapolis, IN, USA).
Histologic analysis
Liver and kidney tissue were fixed in 10% buffered
formaldehyde, and then processed and embedded in par-
affin and sectioned (5m). These sections were stained
with Masson Trichrome, and/or hematoxylin and eosin,
and viewed by light microscopy. A pathologist then per-
formed morphologic evaluation in blinded, randomized
sections of the kidney and liver tissue. Fibrosis was
scored semiquantitatively as normal tissue (0), and mild
(), moderate (), or severe () fibrosis, respec-
tively.
Statistical analysis
Data are expressed in mean  standard error of the
mean (SEM) and P  0.05 was considered significant.
The difference in values between different days in the
same group or between groups of animals with different
treatments was tested using one-way repeated measures
analysis of variance (ANOVA). To examine for differ-
ences in individual points a pair-wise comparison with
paired t tests with Bonferroni’s multiple comparison ad-
justment was used.
RESULTS
General characteristics and metabolic studies
The general characteristics of the animals in all four
groups are shown in Table 1, liver function tests in Table
2, and sodium balance data in Table 3. Based on the
food intake and the vitamin E content of the diet, the
daily vitamin E intake in the untreated rats was 1.57 
0.05 and 1.25 0.08 IU/day/rat (in groups 1 and 3, respec-
tively). The vitamin E–treated rats received 161.89 
6.69 and 156 5.75 IU/day/rat (in groups 2 and 4, respec-
tively). Twenty-one days after bile duct ligation or sham
surgery, the survival rate of both groups of rats that
underwent sham surgery was 100%. In fact, there were
no significant differences between the untreated and vita-
min E–treated control rats in any of the parameters,
except that the vitamin E–treated controls tended to
excrete more sodium. On the other hand, only 67% of
the untreated CBDL rats survived to 21 days. These
CBDL rats had abdominal distension, ascites, jaundice,
and the color of their urine was an intense yellow com-
pared to the weak-yellow urine of the control groups.
Their food intake and body weight was significantly less
than the control groups. The typical increase in kidney
weight/body weight ratio (characteristic of CBDL rats)
was also present. These CBDL rats had portal hyperten-
sion with splenomegaly, increased renal venous pres-
sures, and exhibited prominent sodium retention that
was evident by the end of the first week. Finally, their
hematocrit levels were markedly lower than the control
groups. Morphologic evaluation of the liver (Fig. 1) re-
veals varying degrees of bile duct proliferation and focal
bile infarcts, with mild fibrosis (). The kidneys of these
animals were morphologically normal (data not shown).
In striking contrast, the 21-day survival of the vitamin
E–treated CBDL rats was 100%. Their food intake was
normal, their water intake was increased, and they did
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Table 1. Balance studies, kidney and spleen weight, portal pressure, renal venous pressure, and hematocrit in the different experimental groups
Control Control  Vitamin E CBDL CBDL  Vitamin E
Time after CBDL or sham surgery days 21.780.71 21.200.84 20.900.35 20.380.26
Survival at 21 days % 100 100 67 100
Food intake g/day/rat 31.51.1 32.41.3 25.11.2a 31.41.2
Water intake mL/day/rat 41.22.2 51.39.3 48.35.4 53.71.8a
Body weight g 4398 4518 33515a 4125a,b
Kidney weight g 1.670.1 1.890.2 1.530.1a 1.860.1a,b
Kidney/body weight % 0.3830.021 0.4120.036 0.4970.014a 0.4510.017a
Spleen weight g 0.970.1 0.890.1 1.940.2a 2.200.2a
Portal pressure mm Hg 8.860.45 9.100.92 16.861.03a 15.191.39a
Renal venous pressure mm Hg 2.540.17 2.650.37 4.270.49a 3.610.47
Hematocrit % 39.11.5 42.01.2 30.62.8a 38.61.1b
Groups consisted of untreated rats subjected to chronic bile duct ligation (CBDL), untreated rats subjected to sham surgery (control), rats with CBDL treated
with vitamin E at a dose of 5000 IU/kg diet (CBDL  vitamin E), and control rats treated with vitamin E (control  vitamin E) 21 days past surgery.
a P  0.05 vs. control; b P  0.05 vs. CBDL
Table 2. Liver function parameters in the different experimental groups
Control Control  Vitamin E CBDL CBDL  Vitamin E
(N  5) (N  4) (N  8) (N  7)
ALKP U/L 39672 24824 69279a 66949a
ALT U/L 416 375 340125a 36097a
AST U/L 687 8815 22941017a 1438334a
Total BR mg/dL 0.120.02 0.180.03 8.691.16a 7.740.24a
Abbreviations are: ALKP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BR, bilirubin. Values are expressed as means standard
error.
a P  0.05 vs. control
Table 3. Sodium balance study in the different experimental groups
at day 0, 7, and 20 of CBDL or sham surgery
Day 7 Day 14 Day 20
Sodium balance mEq/day
Control 0.180.18 0.150.11 0.050.17
Control  Vitamin E 0.360.30 0.560.20a 0.960.41a
CBDL 0.640.15a 0.520.13a 0.560.19a
CBDL  Vitamin E 0.150.12b 0.610.14a,b 0.410.25c
CBDL is chronic bile duct ligation.
a P  0.05 vs. control
b P  0.05 vs. CBDL
c P  0.05 with respect to day 14
not retain sodium until after the 14th day. They grew
more than the untreated CBDL rats, but not to the same
extent as the control animals. In addition, their hemato-
crit levels were normal. Despite these improvements,
there was no noticeable difference in the general appear-
ance of these rats compared to the untreated CBDL rats
(they still were jaundiced, had ascites, etc.). There were
no significant improvements in the biochemical parame-
ters of their liver disease or in the hepatic morphology,
which was indistinguishable from the untreated rats (Fig.
1); mild fibrosis remained present to the same extent as
in the untreated CBDL rats (). In addition, their portal
pressures and spleen weights were the same as in the
untreated CBDL rats. As in the other groups, there were
no obvious histologic abnormalities in the kidneys (data
not shown).
Mean arterial pressure in anesthetized rats
Three CBDL rats (2 untreated and 1 treated with
vitamin E) died during the surgical procedures before
the conclusion of the acute experimental procedures and
were thereby excluded from the study. As shown in Fig-
ure 2A, the MAP in untreated CBDL rats was lower
than in untreated control rats (69.2  5.2 vs. 104.89 
4.9 mm Hg, respectively). Administering vitamin E to
CBDL animals completely prevented the CBDL-induced
fall in MAP (MAP was 98.5  3.5 mm Hg). This effect
was not due to a nonspecific vasoconstrictor effect of
vitamin E because it did not alter the MAP of control
rats (MAP was 109  5.7 mm Hg).
The changes in blood pressure were followed by recip-
rocal changes in PRA (Fig. 2B). PRA in the untreated
controls was 10  3 ng/mL/h and this was not altered
by vitamin E treatment (12  5 ng/mL/h). On the other
hand, the untreated CBDL rats had a higher PRA (63 
13 ng/mL/h) that accompanied their hypotension. The
vitamin E–induced increase in MAP was associated with
a decrease in PRA to almost control values (18  4 ng/
mL/h). Please note that the sample numbers are different
because it was not possible to measure PRA in all the
rats (due to insufficient plasma): control  6; control 
vitamin E  5; CBDL  7, CBDL  vitamin E  7.
Telemetry study to determine the development of
hypotension in conscious, CBDL rats
Figure 3 depicts the evolution of systolic and diastolic
blood pressure and MAP in conscious, unrestrained rats.
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Fig. 1. Representative histologic sections of
a chronic bile duct ligation (CBDL) and con-
trol rat liver. (A ) The CBDL rat demonstrates
bile ductular proliferation without significant
portal fibrosis or inflammation when com-
pared with the liver from a (B ) control animal
(Trichrome stain, 100).
Fig. 2. Mean arterial pressure (MAP) (A ) and plasma renin activity
(PRA) (B ) at 21 days post-sham or chronic bile duct ligation (CBDL)
surgery in untreated and vitamin E–treated rats. (*) P  0.05 versus
control; (†) P  0.05 versus CBDL.
In sham-operated rats, the MAP was initially 95  5
mm Hg (day 2, post-surgery) and remained stable
throughout the 21 days; it was 93.0  4 mm Hg at day
21. The MAP in the CBDL rats was not initially different
from controls (104  2 mm Hg on day 2), but it progres-
Fig. 3. Blood pressures in conscious, unrestrained control (left) and
chronic bile duct ligation (CBDL) rats (right). *P  0.005 vs. baseline
(day 2); †P  0.05 vs. baseline (day 2).
sively fell so that it was significantly lower than baseline
by day 14 (90 3 mm Hg), and it reached 77 3 mm Hg
on day 21. Therefore, these studies established that a
progressive decline in blood pressure occurs in conscious
CBDL rats, and that the hypotension is not simply due
to an enhanced response to anesthesia.
Renal function studies
RBF was 6.1 0.9 mL/min/g in the untreated controls
and 8.5  1.3 mL/min/g in the vitamin E–treated control
(Fig. 4A). The corresponding values for renal vascular
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Fig. 4. Renal blood flow (RBF) and glomerular filtration rate (GFR)
in the four experimental groups (control, control  vitamin E, CBDL,
and CBDL  vitamin E) at 21 days. *P  0.05 vs. control; †P  0.05
vs. CBDL. CBDL is chronic bile duct ligation.
resistance (RVR) were 22.16  4.67 and 14.81  2.29
mm Hg/mL/min, respectively. RBF in untreated CBDL
rats was decreased to 2.5  0.4 mL/min/g. This decrease
in RBF was due to vasoconstriction and not to the fall
in MAP, since the RVR was increased to 33.49  4.51
mL/min/g (P  0.05). Vitamin E treatment prevented
this renal vasoconstrictor effect. RBF was 7.9  1.3 mL/
min/g, which correlates to a RVR of 13.67  2.15 mm Hg/
mL/min. The changes in GFR were similar to those in
RBF (Fig. 4B). GFR was 1.05 0.14 and 1.14 0.13 mL/
min/g in the untreated and vitamin E–treated controls,
respectively. CBDL reduced the GFR to 0.51  0.11
mL/min/g and vitamin E restored it to 1.12  0.03 mL/
min/g.
The CBDL rats also had decreased sodium and water
excretion (Fig. 5). Natriuresis was 4.87 1.32 Eq/min/g
in control animals vs. 1.01  0.63 in the CBDL animals,
and diuresis was 28  7 and 12  3 L/min/g, respec-
tively, for untreated controls and CBDL rats. Vitamin
E did not alter natriuresis or diuresis in control rats but
corrected the abnormal sodium and water retention in
the CBDL animals. Natriuresis was 3.83  0.97 and
5.47  1.27 Eq/min/g, whereas diuresis was 31  5 and
23  5 L/min/g in the vitamin E–treated control and
CBDL rats, respectively.
Fig. 5. Diuresis and natriuresis in the four experimental groups (con-
trol, control  vitamin E, CBDL, and CBDL  vitamin E) at 21 days.
*P  0.05 vs. control; †P  0.05 vs. CBDL. CBDL is chronic bile duct
ligation.
Oxidative stress indices in the systemic and
renal circulations
Figure 6 shows the levels of F2-isoprostanes (Fig. 6A)
and TBARS (Fig. 6B) in plasma from the systemic circu-
lation. As is clearly seen in the Figure, both markers of
oxidant stress were significantly increased in the CBDL
rats. F2-isoprostanes were 49.6  8.0 and 105  8.4
pg/mL, and TBARS were 1.2 0.2 and 10.1 0.4g/mL
in untreated control and CBDL rats, respectively. Vita-
min E did not alter the F2-isoprostanes levels in either
control or CBDL rats (48 4.9 and 118.6 11.8 pg/mL,
respectively) but caused small decreases in the TBARS
levels of both groups (0.03  0.03 and 8.3  0.3 g/mL,
respectively).
The concentration of F2-isoprostanes in the renal ve-
nous circulation of the untreated CBDL rats was espe-
cially elevated (much more so than in the systemic circu-
lation), whereas the increase in TBARS was quite similar
to the systemic circulatory levels (Fig. 6 C and D). F2-
isoprostanes were 171  35.1 and 504.2  71.0 pg/mL,
and TBARS were 1.1  0.2 and 8.7  0.7 g/mL in
untreated control and CBDL rats, respectively. How-
ever, in marked contrast to in the systemic circulation,
vitamin E treatment was very effective at decreasing the
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Fig. 6. Levels of free isoprostanes and
TBARS in the (A and B ) systemic circulation
and in (C and D ) renal vein plasma at 21 days.
*P  0.05 vs. control; †P  0.05 vs. CBDL.
CBDL is chronic bile duct ligation; TBARS
is thiobarbituric acid reactive substances.
renal venous F2-isoprostane levels to near normal in the
CBDL rats (212  15.2 pg/mL), without altering the
levels in the control groups (168.8  43.5 pg/mL). Vita-
min E treatment also decreased TBARS levels in both
the control and CBDL rats, but the magnitude of this
decrease was much less and resembled its systemic actions
(0.1  0.05 and 6.7  0.37 g/mL in vitamin E–treated
control and CBDL rats, respectively).
ET levels in the systemic and renal circulations
The concentrations of ET in both the systemic and
renal circulations were markedly elevated in the un-
treated CBDL rats (Fig. 7). ET levels in the untreated
control and CBDL rats were 29 7 and 178 67 pg/mL,
respectively, in systemic circulation, and 5.4  1.43 and
32.6  4.6 pg/mL, respectively, in the renal circulation.
Similar to what we observed with the F2-isoprostanes,
vitamin E decreased the renal venous (albeit not to base-
line), but not systemic, ET levels. Systemic ET levels
were 38 5 and 162 29 pg/mL in the vitamin E–treated
control and CBDL rats, respectively. Renal venous ET
levels were 4.5  0.6 and 18.6  4.6 pg/mL, respectively.
DISCUSSION
The central finding of this study is that preemptive
treatment with vitamin E had dramatic effects in
Sprague-Dawley rats subjected to 21 days of CBDL.
It improved their survival rate and normalized blood
Fig. 7. Levels of endothelin (ET) in the in the (A ) systemic circulation
and in (B ) renal vein at 21 days. *P  0.05 vs. control; †P  0.05 vs.
CBDL. CBDL is chronic bile duct ligation.
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pressure. It also improved renal indices of perfusion,
filtration, and sodium and water handling. However,
these striking effects were in the absence of any signifi-
cant improvement in the liver disease or portal pressure.
Moreover, vitamin E did not convincingly reduce sys-
temic indices of oxidant stress or ET. However, despite
this minimal effect on systemic levels, renal venous levels
of these factors were all reduced, suggesting that vitamin
E may exert a protective effect on CBDL rats by altering
local redox balance within target tissues without effecting
systemic oxidative stress or the liver disease.
CBDL in the rat usually causes severe cholestatic liver
disease complicated by portal hypertension and ascites
and is accompanied by a hyperdynamic circulation that
leads to progressive hypotension, renal dysfunction, and
death (usually within 5 weeks) [12, 27, 31–34]. In the
present study, 33% of our CBDL rats had died by the
21st day, and the surviving rats were all quite ill. They
had significant liver dysfunction, portal hypertension,
splenomegaly, decreased growth, hypotension, marked
renal dysfunction, and a lower hematocrit. These alter-
ations were accompanied by marked increases in the
both systemic and renal indices of oxidant stress. In con-
trast, the vitamin E–treated animals were distinctly
healthier than the untreated CBDL rats. Their growth,
hematocrit, and blood pressure were all markedly im-
proved, and none died during the study period. We have
confirmed this observation in an identical protocol [ab-
stract A4125; Ortiz MC et al, J Am Soc Nephrol 11:789A,
2001] and extended it further in preliminary studies in
which 9 CBDL rats, 4 with vitamin E and 5 without it
were monitored for up to 65 days post-CBDL (unpub-
lished observations). All of the untreated rats had died
by 30 days whereas 3 out of the 4 vitamin E–treated rats
were still alive (two survived past 60 days). We could
not establish the mechanism for the improved 21-day
survival, but it was associated with normalization of blood
pressure and renal function, and did not appear to be due
to amelioration of the liver disease. Indeed, vitamin E
did not improve the cholestasis or liver function (either
by morphology or the liver function tests), decrease por-
tal pressures or spleen weight, and all of the animals still
developed ascites. These findings are, for the most part,
consistent with previous studies, which have reported
that diverse antioxidants have either no effect or only
modestly improve hepatic function and portal pressures
during liver disease [23, 27, 35, 36].
The untreated CBDL rats of the present study were
markedly hypotensive. In fact, they tended to be more
hypotensive than in several previous studies [32, 37–40].
However, this degree of hypotension is not a unique
finding [41–45]. The reasons for the variability in blood
pressure between the diverse studies are unknown but
may reflect differences in experimental model, severity
of illness, species/strain, or anesthesia. Our animals may
be more hypotensive due to a combination of the follow-
ing factors. First, the severity of illness in our experimen-
tal model of CBDL is high because we performed a
double ligation with bisection of the bile duct, which
ensures complete obstruction, leading to a severe form
of cholestasis with relatively early death. Second, subtle
differences in strain may have played a role. In this
respect, it is interesting to note that the blood pressure
in our control rats was low but consistent with those
previously reported in Sprague-Dawley rats obtained
from Charles River, which are lower than in those ob-
tained from Harlan [9, 46]. Consequently, the higher
blood pressure in CBDL rats in certain studies may re-
flect a higher baseline blood pressure of their rats [38, 44].
For instance, in the report by Bosch-Marce´ et al [38],
the MAP was 93  3 mm Hg in their cirrhotic rats, but
it was 124  3 mm Hg in their control rats. Thus, the
difference in MAP between the CBDL and control rats
(30 mm Hg) was comparable to that in our present
study. Finally, it is worth mentioning that although liver
disease can increase the susceptibility to anesthesia
[32, 44], this does not explain the hypotension in our
animals because they were hypotensive in the conscious,
unrestrained state, as well.
The mechanisms by which liver disease leads to a hyp-
erdynamic circulatory state with the resultant hypoten-
sion are incompletely understood [33], but it appears that
an increase in oxidative stress is an essential component.
This contention is based on previous studies [27], which
found that the antioxidants 	-lipoic acid and N-acetyl
cysteine prevented the hyperdynamic circulation induced
by either experimental cholestasis or portal hypertension.
Our study further supports this notion, as vitamin E
prevented the fall in blood pressure and restored PRA
to normal (likely because of the improved hemodynamic
state). However, this improvement occurred without a
convincing decrease in the systemic oxidative stress mark-
ers, which, taken together with the fact that we used a
very high dose of vitamin E, raises the possibility that
its beneficial effect on blood pressure was independent
of its antioxidant properties [47]. However, we think that
this possibility is not likely because the two antioxidants
(N-acetyl cysteine and 	-lipoic acid) used in the previous
studies [23, 27] are unrelated to vitamin E, yet they had
similar effects on systemic hemodynamics. Curiously, in
one of the studies [27], 	-lipoic acid was also ineffective
at reducing systemic levels of oxidant stress markers
during CBDL, despite normalization of hemodynamics.
The lack of a reduction in systemic levels of oxidant
stress may be because our markers are not sensitive
enough to detect the improvement in the redox state.
However, we think that it is more likely that there is
compartmentalization of the antioxidant efficacy (i.e.,
hepatic or renal oxidative stress may have been reduced
without a reduction in systemic oxidative stress). In this
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regard, it is interesting to note that renal vein levels of
F2-isoprostanes (one of the more sensitive markers of
oxidative stress [48]) were decreased to control levels.
Overall, we believe that these studies strongly suggest
that oxidative stress plays a key role in the pathogenesis
of the systemic vasodilation during liver disease.
The mechanisms by which antioxidants increase blood
pressure during liver disease are presently unresolved.
However, it is important to note that antioxidants are
not vasoconstrictors so their beneficial action is not likely
due to a nonspecific vasoconstrictor effect. In fact, one
might have expected the antioxidants to worsen the hy-
potension because antioxidants lower blood pressure in
other conditions [30, 49]. Furthermore, antioxidants
lower blood pressure by augmenting the effect of nitric
oxide (NO), which is increased during liver disease, and
blocking NO prevents cirrhosis-induced hypotension [28,
47, 50]. Accordingly, the effect of vitamin E in our study
seems paradoxical. However, this is not necessarily the
case because there are circumstances in which oxidative
stress induces NO; thus, in these situations antioxidants
would reduce NO. Oxidative stress can induce NO by
increasing eNOS activity because when superoxide fuses
with NO, it forms peroxynitrite. Peroxynitrite then acti-
vates the phosphoinositide 3-kinase/AKT pathway [51],
which in turn phosporylates eNOS, increasing its activity
[52]. Oxidative stress can also increase iNOS (perhaps
via nuclear factor-
B), and antioxidants reduce lipopoly-
saccharide-induced iNOS expression [53, 54] and vascu-
lar hyporeactivity [55]. Thus, vitamin E may restore vas-
cular responsiveness during CBDL by preventing the
overexpression of eNOS and/or iNOS, thereby reducing
NO. While this possibility needs further investigation it
is interesting to point out that two studies have reported
that N-acetyl cysteine or 	-lipoic acid reduce nitrates
during partial portal vein occlusion or CBDL [23, 27],
thus supporting this possibility.
In addition to having hypotension, the CBDL rats had
a profoundly decreased RBF. The low RBF was likely
due to the interplay between the hypotension combined
with intense renal vasoconstriction. That is, hypotension
likely contributed to the fall in RBF, but several pieces
of evidence suggest that abnormal renal vasoconstriction
was present. First, RBF was much lower than expected
for the corresponding MAP. In fact, we directly explored
this in a separate group of normal rats by measuring RBF
while progressively decreasing renal perfusion pressure
(via a suprarenal aortic clamp). Decreasing renal perfu-
sion pressure to approximately the same pressure (70
mm Hg) that our CBDL rats had had little effect on RBF
(8 mL/min/g). In fact, we had to reduce renal perfusion
pressure to 30 mm Hg in order to obtain RBF levels
that approached those of the CBDL rats (3.3 mL/min/g),
suggesting that autoregulation is shifted down and to the
right during CBDL (a pattern that is consistent with renal
vasoconstriction). Second, RVR was increased in CBDL
rats, indicating that renal vasoconstriction, rather than
autoregulatory vasodilation, was present. Third, in the
telemetry experiments, we found that the creatinine
clearance fell in CBDL rats before any changes in MAP
were detected, also suggesting renal responses that are
distinct from the systemic hemodynamic effects. Finally,
in separate studies we increased renal perfusion rates in
CBDL rats to the same levels as in control rats, but this
normalization of perfusion rates did not normalize renal
vascular filling [abstract A4125; Ortiz MC et al, J Am
Soc Nephrol 11:789A, 2001]. Taken together, these ob-
servations provide compelling evidence that renal vaso-
constriction is present in our CBDL model, which, to-
gether with the hypotension, cause a marked fall in RBF.
While this degree of renal vasoconstriction is well known
to occur during cirrhosis (even before renal dysfunction
becomes apparent) [2, 56–58], it is more variable in the
CBDL rats. Some studies have found decreases in RVR
[32, 34, 44], while others have found either no change
or an increase in RVR, both of which suggest renal
vasoconstriction or impaired autoregulatory vasodilation
[6–10, 45, 59, 60]. The reasons for these discrepancies
are not clear but may be related to subtle differences in
the rat (e.g., strain, breeder, etc.), anesthesia, or the
severity of the disease. We suggest that a key consider-
ation is likely related to the severity of illness. Indeed,
we previously found that rats with less severe liver dis-
ease had localized cortical vasoconstriction [10]. Thus,
these studies may suggest that as liver disease advances,
renal vasoconstriction progresses from the cortex toward
the medulla.
Vitamin E therapy not only normalized blood pressure
but also preserved RBF. This protective effect on RBF
was due likely in part to the increase in blood pressure,
but also because vitamin E prevented CBDL-induced
renal vasoconstriction (RVR fell significantly). This ef-
fect appears to be unique to vitamin E because other
agents that have been used to increase blood pressure
do not have as beneficial an effect on RBF as vitamin E
[42, 43, 45, 61–68]. The contrasting actions of vitamin E
in the systemic and renal vasculature may be explained
by an imbalance between vasoconstrictor and vasodila-
tor factors in the systemic and intrarenal circulation.
That is to say, in the untreated CBDL rats, vasodilators
(e.g., NO) may predominate in the systemic circulation
and thus lead to hypotension. But this hypotension leads
to subsequent activation of vasoconstrictor systems (e.g.,
renin-angiotensin, ET) with the consequential increase
in intrarenal levels of various vasoconstrictors (angioten-
sin II, F2-isoprostanes, ET, etc.). Thus, the increased
intrarenal concentration of these factors, together with
the exquisitely high sensitivity of the renal vasculature
to them, may lead to selective renal vasoconstriction. In
fact, a vicious cycle may ensue because systemic hypoten-
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sion increases angiotensin II formation, which in turn
increases oxidative stress and F2-isoprostanes, with the
subsequent stimulation of ET formation [20, 21]. As sys-
temic hemodynamics worsen, the cycle intensifies, thus
leading to profound renal vasoconstriction. In addition,
increased local quenching of NO by superoxide (sug-
gested by the high intrarenal levels of F2-isoprostanes)
may leave the kidney susceptible to the unopposed ef-
fects of these vasoconstrictors. The increase in intrarenal
angiotensin II and ET may explain why angiotensin-
converting enzyme inhibitors (ACEI) [40], or ET antago-
nists [69] improve renal hemodynamics in cirrhotic rats.
However, the use of these agents is severely limited be-
cause blood pressure tends to fall precipitously. In the
present study, vitamin E improved blood pressure while
normalizing renal perfusion, likely by restoring the nor-
mal equilibrium between intrarenal vasoconstrictors and
vasodilators. Specifically, it decreased renal oxidant stress
with the ensuing fall in F2-isoprostanes and ET, and per-
haps increased renal NO; and it increased blood pressure,
thus decreasing PRA and consequently angiotensin II,
which would further decrease oxidant stress and ET for-
mation. Thus, it is tempting to postulate that vitamin E
may be particularly useful in treating CBDL-induced
renal dysfunction as it breaks the vicious cycle between
hypotension and renal vasoconstriction that appears to
be of key importance in the deterioration of renal func-
tion. Finally, because increases in renal venous pressure
can cause redistribution of RBF and sodium retention in
the kidney [70], we cannot completely exclude the possi-
bility that the vitamin E–induced improvement in renal
perfusion was due to the reduced renal venous pressure.
However, this seems unlikely, as the reduction in venous
pressure was minor and did not approach control values.
Despite the ability of vitamin E to normalize natriure-
sis and diuresis in the CBDL rats, these rats still devel-
oped ascites, indicating that sodium retention must have
occurred at some point. This apparent contradiction may
be explained by the following. Vitamin E improved the
kidney’s ability to excrete salt and water (as suggested
by the normalization of these parameters in the acute
studies at 21 days). Despite this improvement, the con-
scious CBDL rats still retained sodium during the 21
days (perhaps due to hypotension or renal abnormali-
ties), thus causing the ascites. In this respect, it is interest-
ing to note that while vitamin E did seem to delay net
sodium retention (as suggested by Table 3), there is
clearly sodium retention in the vitamin E–treated group
toward the end of 21 days. Thus, we think that there
were periods during the 21 days in which the treated
rats retained sodium, thus leading to the ascites. Whether
there were differences in ascites formation between un-
treated and vitamin E–treated CBDL rats was not as-
sessed in the present study, although in a separate group
of rats we found no discernible differences [10]. Finally,
the differences in water intake and growth rate between
groups may also have contributed to the disparity be-
tween renal excretory function and ascites formation.
The changes in hematocrit in the various groups merit
comment. In the chronic phase of the CBDL model, a
low hematocrit is not unexpected in view of a number
of pathophysiologic alterations present in this model,
and which, singly or in combination, may contribute to a
low hematocrit: extracellular fluid expansion, subclinical
blood loss, low grade disseminated intravascular coagu-
lation, suppressive effects of liver and renal failure on
effective erythropoeisis. A notable finding in our study
was that the supplementation of vitamin E in the diet
of the CBDL rats led to a significant improvement in
hematocrit. While the elucidation of this effect is beyond
the scope of the present study, this improvement in he-
matocrit may reflect several possibilities. This increase
in hematocrit may be part of the general clinical improve-
ment afforded by vitamin E therapy, and thus, germane
to the prevention of overall mortality and the improve-
ment in somatic growth we observed with such vitamin
E supplementation. We also offer the speculation that
vitamin E supplementation may provide cytoprotection
at a local level to the erythrocyte such that enrichment
in vitamin E in erythrocytic membranes may render
erythrocytes relatively resistant to lytic effects caused by
disseminated intravascular coagulation (as occurs in liver
failure), or from the detergent and other damaging ef-
fects of bile acids that are present in copious amounts
in the circulation. It is tempting to speculate that dietary
enrichment with vitamin E may confer regional protec-
tion at the level of tissues, in this case, the erythrocyte,
in much the same way that regional protection was con-
ferred to the kidney by this dietary enrichment without
necessarily evincing alterations in systemic indices of
oxidative stress.
CONCLUSION
Treating CBDL rats with vitamin E strikingly im-
proved systemic blood pressure, renal hemodynamics,
and excretory function, which led to a greater 21-day
survival of these rats, despite the lack of improvement
in liver function or portal pressures. These results con-
firm the importance that renal function and systemic
hemodynamics have in determining the outcome in this
and perhaps other related models of liver disease. Addi-
tionally, because intrarenal, but not systemic, markers of
oxidative stress improved, it would appear that vitamin E
exerts its protective effect by altering local redox balance
within target tissues and by restoring a favorable renal
hormonal profile (e.g., ET, angiotensin II). While the
underlying insult (bile acids, hyperbilirubinemia, endo-
toxin, etc.) remains unknown, our findings highlight the
importance of oxidative stress in initiating and/or perpet-
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uating the hemodynamic and renal disturbances during
CBDL. Finally, it raises the intriguing possibility that
antioxidants, with their beneficial effects on both renal
and systemic circulation, may be particularly beneficial
as adjunctive therapy in the treatment of patients with
cirrhosis and ascites.
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